Work

Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.79

Authors: Rana R. McKay, Wanling Xie, Rosina Lis, Huihui Ye, Zhenwei Zhang, Quoc-Dien Trinh, Steven Lee Chang, Lauren Christine Harshman, Ashley Ross, Kenneth J. Pienta, Daniel W. Lin, William J Ellis, Robert B. Montgomery, Peter Chang, Andrew Wagner, Glenn Bubley, Adam S. Kibel, Mary-Ellen Taplin

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard University, Stanford Medicine, Stanford University, Johns Hopkins Medicine, Johns Hopkins University, University of Washington, Dana-Farber Brigham Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791707002

Cites:

Cited by: 3

Related to: 10